Advanced epitope peptide of hantavirus nucleocapsid protein and application of dominant epitope peptide in preparation of anti-hantavirus vaccine
By screening and identifying MHC-II antigenic nopolypeptide and dominant epitope peptide sequences, the cellular immune response of hantavirus nucleocapsid protein was activated, and the problem of low immune response in the prior art was solved, and efficient The anti-hantavirus vaccine has achieved an effective immune response to hantavirus.
Patent Information
- Application Number
- CN202411228990.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-22
AI Technical Summary
The lack of effective hantavirus nucleocapsid protein antigen peptides in the prior art leads to low immune response and it is difficult to design an efficient anti-hantavirus vaccine.
MHC-II antigenic nonapeptide and dominant epitope peptide sequences, such as LVIARQKVR, YVSLPNAQS and ILQDMRNTI, were screened and identified to activate cellular and humoral immune responses, and a hantavirus vaccine based on these epitopes was designed.
The high reactivity and protectiveness of these epitopes were verified through the ELISpot assay, providing a new idea for the design of the Hantavirus vaccine, which can activate effective specific cellular and humoral immune responses, and has broad application prospects.
Smart Images

Figure CN118994306A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microbial immunity, and specifically relates to a dominant epitope peptide of a Hantavirus nucleocapsid protein and an application thereof in preparing an anti-Hantavirus vaccine. Background Art
[0002] Hemorrhagic fever with renal syndrome (HFRS) is a rodent-borne disease caused by Hantavirus, which is endemic in Europe and Asia. In the past few decades, 70-90% of HFRS cases have been reported worldwide. The mortality rate is about 2-10%. Hantaan virus belongs to the Hantaviridae family, the Orthohantavirus genus, and the Bunyavirales order. HTNV is a negative-sense single-stranded RNA virus with a genome consisting of three segments: large (L), medium (M), and small (S), encoding RNA-dependent polymerase, envelope glycoprotein (GP), and nucleocapsid protein (NP), respectively. NP has multiple folds and can form a fairly rigid helix with a diameter of 10 nm within the virus and during cell infection. NP is specific and essential for the viral cycle. NP can also regulate the transcription of the related apoptosis-inducing ligand (TRAIL) and its receptor, and TRAIL can inhibit apoptosis and increase the production of HTNV, so NP has become an attractive potential target for antiviral drugs.
[0003] During the immune response in vivo, CD4 + T cells mainly recognize antigens presented by major histocompatibility complex (MHC)-II, become activated, and then assist in cellular and humoral immune responses. + T cell recognition of viral peptides plays an important role in resisting viral infection. However, only peptides with high affinity and tight binding to MHC class II molecules can be expressed on the surface of APC cells and presented to CD4 + T cells recognize and thus initiate an immune response. Therefore, immunogenic epitopes are crucial for elucidating antiviral immunity. At the same time, antigenic conservation is also crucial for pathogen-host interactions and the establishment of herd immunity. The existence of evolutionarily conserved epitopes is essential for viral survival, so long-term immunity to these viruses due to epitope conservation may provide broad protection regardless of their strains.
[0004] Recently, epitope-based strategies have been used for alternative vaccine design and immunotherapy. Rational design of epitope-based vaccines is very promising because it improves safety by reducing viral components that cause adverse reactions, and can cover a wide range of people through multi-epitope combinations, thereby ultimately improving vaccine efficiency. Currently, there are few known HTNV NP antigenic peptides that can effectively activate the body's immune response, and the immune response reactivity is low. Therefore, it is urgent to screen and identify new HTNV NP antigenic peptides with high immune response reactivity. Summary of the invention
[0005] In view of the above technical problems, one of the objects of the present invention is to provide an MHC-II class antigenic nonapeptide, wherein the amino acid sequence of the nonapeptide is one of the following:
[0006] SEQ ID NO.10: LVIARQKVR;
[0007] SEQ ID NO.11: YVSLPNAQS;
[0008] SEQ ID NO.12: ILQDMRNTI.
[0009] The MHC-II class antigenic nonapeptide of the present invention can activate effective specific cellular immune response and humoral immune response, providing a new idea for subsequent immunological research related to Hantavirus (HTNV76-118), and contributing to the future design of epitope-based anti-HTNV epitope vaccines.
[0010] The second object of the present invention is to provide a gene encoding the MHC-II class antigenic nonapeptide.
[0011] The third object of the present invention is to provide a dominant epitope peptide of a Hantavirus nucleocapsid protein comprising the nonapeptide, wherein the amino acid sequence of the dominant epitope peptide is one of the following:
[0012] SEQ ID NO.1:NAHEGQLVIARQKVR;
[0013] SEQ ID NO.2:AHEGQLVIA RQKVRD;
[0014] SEQ ID NO.3: HEGQLVIARQKVRDA;
[0015] SEQ ID NO.4: EGQLVIARQKVRDAE;
[0016] SEQ ID NO.5: GQLVIARQKVRDAEK;
[0017] SEQ ID NO.6: KPKHLYVSLPNAQSS;
[0018] SEQ ID NO.7: LYVSLPNAQSSMKAE;
[0019] SEQ ID NO.8: FSILQDMRNTIMASK;
[0020] SEQ ID NO.9: SILQDMRNTIMASKT;
[0021] Among them, the common amino acid fragments of the dominant epitope peptides shown in SEQ ID NO.1 to 5 are shown in SEQ ID NO.10, SEQ ID NO.6 to 7 contain the nonapeptide shown in SEQ ID NO.11, and the common amino acid fragments of the dominant epitope peptides shown in SEQ ID NO.8 to 9 are shown in SEQ ID NO.12.
[0022] A fourth object of the present invention is to provide a gene encoding the dominant epitope peptide.
[0023] The fifth object of the present invention is to provide the use of the MHC-II class antigenic nonapeptide or the dominant epitope peptide in the preparation of anti-Hantavirus products.
[0024] The sixth object of the present invention is to provide the use of the gene in the preparation of anti-Hantavirus products.
[0025] Furthermore, the product is an epitope vaccine.
[0026] The seventh object of the present invention is to provide a Hantavirus epitope vaccine, whose immunogen is derived from the MHC-II class antigenic nonapeptide or the dominant epitope peptide.
[0027] Furthermore, the vaccine also includes a pharmaceutically acceptable carrier.
[0028] Furthermore, the vaccine may or may not contain an adjuvant.
[0029] Compared with the prior art, the present invention has the following beneficial effects:
[0030] The present invention validated potential epitopes derived from HTNV NP (gene number: P05133.1) by ELISpot test, and conducted multiple in-depth analyses of its protective properties in different isolates from around the world to validate the selected dominant isolates. We further clarified the binding ability of these epitopes to MHC class II molecules and the immune response effect, and confirmed that the immunological properties of the above dominant epitope peptides are determined by their nonapeptide core, which will ultimately help understand the immunobiology of HTNV NP and improve the design of epitope vaccines against the virus in the future.
[0031] The dominant epitope peptides of the present invention can be regarded as viral subunits that can effectively activate the body's cellular immune response and humoral immune response, that is, highly conserved regions required for the function of the virion. Peptide vaccines can be designed based on this. The purpose of this strategy is to inoculate "the smallest structure composed of clear antigens" to activate effective specific cellular immune response and humoral immune response. It has incomparable advantages over traditional vaccines, and is safe and convenient to use, and has broad application prospects in the antiviral process. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 The number of high-affinity dominant epitopes for HTNV NPs by mouse and human MHC class II subtypes was predicted for the four prediction tools.
[0033] Figure 2 Hierarchical clustering analysis of all 15 predicted peptides of HTNV NP. The direction indicated by the arrows indicates the affinity from strong to weak.
[0034] Figure 3 Analysis of affinity, immunogenicity and conservation of MHC class II restricted dominant epitopes of HTNV NP.
[0035] Figure 4 This is a bubble diagram of the docking of 34 dominant epitopes with high affinity, strong immunogenicity, and conserved between and within species with MHC class II molecules.
[0036] Figure 5 ELISPOT verification of the immunogenicity of the preferred epitope peptides. In the figure, 15mer_HTNV-NP.012-016 corresponds to the polypeptides shown in SEQ ID NO.1-5 and SEQ ID NO.10, 15mer_HTNV-NP.173 corresponds to the polypeptides shown in SEQ ID NO.6 and SEQ ID NO.11, 15mer_HTNV-NP.177 corresponds to the polypeptides shown in SEQ ID NO.7 and SEQ ID NO.11, and 15mer_HTNV-NP.332-333 corresponds to the polypeptides shown in SEQ ID NO.8-9 and SEQ ID NO.12. DETAILED DESCRIPTION
[0037] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0038] Example 1: Obtaining the dominant epitope peptide of Hantavirus (HTNV 76-118) nucleocapsid protein
[0039] 1. Amino acid sequence search:
[0040] The nucleocapsid protein (NP, accession number: P05133.1.1) of Hantavirus (HTNV76-118) was obtained from the NCBI GenBank database as input for various bioinformatics tools for epitope prediction, conservation analysis, molecular docking and experiments.
[0041] 2. Epitope prediction:
[0042] For H2-IAb, H2-IAd, H2-IAk, H2-IAs, H2-IAu, H2-IEd, H2-IEk epitope prediction, web-based tools such as IEDB method (http: / / tools.iedb.org / mhci / ), SMMPMBEC from the immune epitope database (http: / / tools.immuneepitope.org / mhci / ), NetMHCpan 4.0 (http: / / www.cbs.dtu.dk / services / NetMHCpan / ) and SYFPEITHI (http: / / www.syfpeit hi.de / bin / MHCServer.dll / EpitopePrediction.htm) are recommended for prediction, and the predicted epitopes that account for the top 2% of the total epitopes are selected. Finally, epitopes predicted by at least two prediction tools are selected for subsequent in-depth analysis.
[0043] Human major leukocyte antigen (HLA)-II class subtype allele epitopes, such as HLA-DRB1 (HLA-DRB1*0101, HLA-DRB1*0301, HLA-DRB1*0401, HLA-DRB1*0405, HLA-DRB1*0701, HLA-DRB1*0802, HLA-DRB1*0901, HLA-DRB1*1101*, HLA-DRB1*1201, HLA-DRB1*1302, HLA-DRB1*1501), HLA-DRB3 / 4 / 5 (HLA-DRB3*0101, HLA-DRB3*0202, HLA-DRB4*0101, HLA-DRB5*0101), HLA-DQA1 / DQB1 (HLA-DQA1*01 01 / DQB1*0501, HLA-DQA1*0102 / DQB1*0602, HLA-DQA1*0301 / DQB1*0302, HLA-DQA1*04 01 / DQB1*0402, HLA-DQA1*0501 / DQB1*0201, HLA-DQA1*0501 / DQB1*0301), HLA-DPB1(H LA-DPA1*0103 / DPB1*0201, HLA-DPA1*0103 / DPB1*0401, HLA-DPA1*0201 / DPB1*0101, HLA-DPA1*0201 / DPB1*0501, HLA-DPA1*0201 / DPB1*1401, HLA-DPA1*0301 / DPB1*0402). Cumulative coverage of MHC class II subtypes exceeding 98% of the population, epitope prediction using the same tools mentioned above. Ultimately, all top 2% epitopes of the respective subtypes predicted by these tools were selected for subsequent studies.
[0044] For mouse MHC class II subtypes, epitopes that appeared 2 or more times in the 4 prediction software were considered dominant epitopes. For human HLA class II subtypes, all 15 peptides that appeared in the top 2% of the prediction results were considered dominant epitopes. As described above, bioinformatics analysis was performed using a variety of computational tools to predict potential MHC class II epitopes with different binding affinities across HTNV nucleocapsid proteins. Mouse H2 subtypes (H2-IAb, H2-IAd, H2-IAk, H2-IAs, H2-IAu, H2-IEd, H2-IEk) and major HLA class II subtype alleles were analyzed. The 15-peptide affinity prediction of the HTNV nucleocapsid protein derived 415 peptides. Figure 1The number of dominant epitopes generated by each prediction tool is listed. After recalculating and excluding repeated 15-peptides, we obtained 10 dominant epitopes in the H2 subtype and 71 dominant epitopes in the HLA class II subtype. In the H2 subtype, H2-IAb has the largest number of dominant epitopes, which is 8 15-peptides. In the HLA class II subtype, HLA-DRB1 has the largest number of dominant epitopes, which is 32 15-peptides, far more than the other four HLA class II subtypes.
[0045] 3. Peptide synthesis:
[0046] The corresponding peptides were synthesized according to the predicted peptide sequence. All peptides used in the experiment were completed by Shanghai Qiangyao Biotechnology Co., Ltd. with a purity of 95% and 1 mg / peptide. After centrifugation of the synthesized peptide powder, 20 μL of dimethyl sulfoxide (DMSO) was added to dissolve it, and then 480 μL of sterile ddH2O was added to mix well and frozen in a -20°C refrigerator for later use.
[0047] 4. Computer analysis:
[0048] (1) 15-peptide cluster analysis: 415 15-peptide clusters were used to study the similarities of different MHC class II molecules in presenting antigens. After normalization of NetMHCpan data, bidirectional hierarchical clustering was performed using the pheatmap software package (version 1.0.12), and expression values were presented as heat maps. Figure 2 The differences between different MHC class II subtypes were shown. The 34 MHC class II molecules were divided into three groups, including the HLA-II class subtype exclusive group, the cross-reactive group (H2 subtype-dominated) and the cross-reactive group (HLA-II class subtype-dominated). HLA-DQA10101-DQB 10501, HLA-DQA10501-DQB10201, HLA-DQA10401-DQB 10402, HLA-DQA10301-DQB 10302 and other genotypes were classified as the HLA-II class subtype exclusive group, suggesting that the above genotypes have similar characteristics in the antigen presentation process. In the cross-reactive (H2 subtype-dominant) group, there were mouse genotypes H2-IAk, H2-IAs, H2-IAu, and H2-IAb, as well as human genotypes HLADQA10102-DQB 10602 and HLA-DQA10501-DQB 10301. This finding suggests that some mice can mimic the immune response of the human body. The same phenomenon was also found in the cross-reactive (HLA-II class subtype-dominant) group, indicating that mice with H2-IAd, H2-IEd, and H2-IEk genotypes can mimic the immune response characteristics of a wider range of people.
[0049] (2) Immunogenicity analysis: High-affinity peptides may not be sufficient to induce an immune response. In addition to immunoreactivity, antigens should also be immunogenic. Immunogenicity is determined by the amino acid sequence. VaxiJen2.0 (http: / / www.ddg-pharmfac.net / vaxijen / VaxiJen / VaxiJen.html) was used to perform immunogenicity analysis on the 74 15-peptide high-affinity epitope prediction epitopes screened out. The analysis results used a probability score > 0.5 as a positive standard, and the peptide was considered to be immunogenic; otherwise, it was not immunogenic. Therefore, 34 of the 74 HTNV NP predicted 15 peptides were judged to be immunogenic. Specifically, 31 of the 71 HLA class II subtype dominant epitopes had immunogenicity, and 9 of the 10 H2 subtype dominant epitopes had immunogenicity.
[0050] (3) Conservatism analysis
[0051] In order to determine the evolutionary conservation of the dominant epitopes in the NP sequence of HTNV 76-118 strain, we used the Blastp (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi) tool to predict the inter-species and intra-species conservation of 15 peptide epitopes with high affinity and strong immunogenicity. Among them, the evaluation criteria for inter-species conservation are Orthohantavirus (taxid: 1980442) except Hantaan virus (HTNV, taxid: 1980471), human (Human, taxid: 9606), and mouse (Mouse, taxid: 10088); and the evaluation criteria for intra-species conservation are Hantaan virus (Hantaanhantavirus, taxid: 1980471) except Hantaan virus 76-118 (Hantaan virus 76-118, taxid: 11602), human (Human, taxid: 9606), and mouse (Mouse, taxid: 10088). In the analysis results, if the E value < 10 -5 , it is considered conservative, so the dominant epitopes can be divided into four categories according to the conservation status: interspecies-intraspecies-; interspecies-intraspecies+; interspecies+intraspecies-; and interspecies+intraspecies+.
[0052] Multiple sequence alignments determined the conservation status of the dominant epitopes in HTNVNP. Figure 3 The statistical results of conservation analysis of all high-affinity and strong immunogenic epitopes are listed.
[0053] The statistical results of the analysis of pan-MHC class II dominant epitopes are as follows: Figure 3It can be seen that the dominant epitopes are conserved both within and between species, which indicates that NP antigens have broad applicability in vaccine design.
[0054] (4) Peptide-MHC molecule docking
[0055] Determining the structure of the epitope peptide-receptor complex is necessary for understanding the molecular mechanism of the relevant biological process and vaccine design. The docking simulation of 15-mer pMHC-II molecules was performed using the EpiDock server (http: / / www.ddg-pharmfac.net / epidock / EpiDockPage.html). After entering the 15-mer peptide sequence, the corresponding MHC-II subtype was selected for docking simulation. Each 15-mer peptide was subjected to molecular docking simulation with the corresponding MHC-II molecule through 7 9-mer determinants, so that the score of each peptide binding to the MHC-II molecule and the docking threshold can be obtained. 15-mer peptides with scores higher than or equal to the given threshold are considered to be true conjugates; otherwise, they are not. After standardizing the binding score data, those with scores higher than the overall median are considered to be bindable and are called bindable cores. Among them, the strongest binding core is called the best core cohesion. Docking is demonstrated by drawing a bubble chart in R Studio (R Studio, Boston, USA).
[0056] We selected 34 dominant epitopes with high affinity, strong immunogenicity, and conservation across species and within species for docking with MHC class II molecules. Among multiple docking results, we used the best core cohesion to describe the situation with the closest docking force, and used the number of bindable cores to describe the possible situations that can be docked.
[0057] from Figure 4 It can be seen that all 34 epitopes docked well with more than one MHC class II molecule. Among them, epitopes RQMISPVMSVIGFLA and QSMGIQLGQRIIVLF docked well with almost all MHC class II molecules. MHC genotypes DPA1*0103 / DPB 1*0201, DPA 1*0201 / DPB 1*0501, DQA 1*0101 / DQB 1*0501, and DQA 1*0102 / DQB 1*0602 docked well with almost all epitopes. All these genotypes may have a stronger immune response to HTNV. The results of molecular docking further illustrate the accuracy of affinity analysis at the molecular level.
[0058] 5. ELISpot test verification:
[0059] A pool of 14 artificially synthesized HTNV NP 15 peptides with the same nonapeptide core for 34 high-affinity, highly immunogenic, and conserved dominant epitopes across species and within species was diluted at a concentration of 20 mg / mL in a sterile PBS solution for ELISpot assay. The cellular immune response to the NP epitope was evaluated by interleukin (IL)-2 ELISpot assay according to the manufacturer's protocol (BD Pharmingen, Franklin Lakes, New Jersey, USA). Briefly, the IL-2-specific capture antibody was diluted with 5 μg / mL (1:250) sterile PBS and placed on the coated ELISpot plate at 4°C overnight. The mice were sacrificed, their spleens were dissected, and the mononuclear cell suspension was ground. After red blood cell lysis, the spleen cells were rinsed and resuspended. After blocking the ELISpot plate with RPMI-1640 containing 10% fetal bovine serum for 2 hours at room temperature, 1×10 6 splenocytes and stimulated with synthetic NP peptide at a final concentration of 5 μg / mL. The plates were cultured in a 5% CO2 incubator at 37°C for 24 h. Complete medium was used as a negative control. ConA (10 μg / mL) was used as a positive control. After incubation, the culture plates were washed with H2O and PBST, and then incubated with 2 mg / mL of the relevant biotinylated rat anti-mouse IL-2 antibody at room temperature for 2 h. After washing with PBST (0.05% Tween20), the plates were incubated with 1:100 streptavidin-horseradish peroxidase (streptavidin-HRP) for 1 hour, 3-amino-9-ethylcarbazole (AEC; DAKEWEI, Shenzheng, China) was added to the HRP substrate, and the reaction was terminated by washing with water. After air drying, we used a CTLELISpot reader (Kennesaw, Atlanta, GA, USA) to count the IL-2 spots produced by the AEC substrate. Each experiment was performed in triplicate, and all results are shown as 10 6 The bar graph was drawn using GraphPad Prism 8.0.1.
[0060] The above 14 groups of HTNV NP 15 peptide pools were used for ELISpot test validation. The peptides were used to stimulate the spleen cells of mice inoculated with inactivated HTNV and observe the secretion of IL-2. IL-2 is secreted by T cells to enhance the cellular immune response in the body, so it is an effective indicator of epitope-activated immune response. The results are shown in Figure 5As shown, the immunoreactivity in BALB / c mice was significantly greater than that in C57 mice, indicating that HTNV NPs have stronger immunoreactivity in H2-d genotype mice. There are also differences in the immunoreactivity of antigenic epitopes in mice of the same strain. We found that 9 dominant epitopes were highly reactive epitopes for T cell immune response, which verified the accuracy of the bioinformatics method in mice. The amino acid sequences of dominant epitopes with high T cell immune response are as follows:
[0061] SEQ ID NO.1:NAHEGQLVIARQKVR;
[0062] SEQ ID NO.2:AHEGQLVIA RQKVRD;
[0063] SEQ ID NO.3: HEGQLVIARQKVRDA;
[0064] SEQ ID NO.4: EGQLVIARQKVRDAE;
[0065] SEQ ID NO.5: GQLVIARQKVRDAEK;
[0066] SEQ ID NO.6: KPKHLYVSLPNAQSS;
[0067] SEQ ID NO.7: LYVSLPNAQSSMKAE;
[0068] SEQ ID NO.8: FSILQDMRNTIMASK;
[0069] SEQ ID NO.9: SILQDMRNTIMASKT;
[0070] Among them, the common amino acid fragments of the dominant epitope peptides shown in SEQ ID NO.1 to 5 are shown in SEQ ID NO.10, SEQ ID NO.6 to 7 contain the nonapeptide shown in SEQ ID NO.11, and the common amino acid fragments of the dominant epitope peptides shown in SEQ ID NO.8 to 9 are shown in SEQ ID NO.12.
[0071] SEQ ID NO.10: LVIARQKVR;
[0072] SEQ ID NO.11: YVSLPNAQS;
[0073] SEQ ID NO.12: ILQDMRNTI.
[0074] Example 2: Application of dominant epitope peptides of Hantavirus (HTNV76-118) nucleocapsid protein
[0075] The present invention lays a foundation for the research of new genetic engineering vaccines of HTNV by predicting the dominant MHC class II epitope peptides on HTNV NP, performing various computer analyses, and verifying the ELISpot test. The above experimental studies have found that the dominant MHC class II epitope peptides on HTNV NP can effectively activate the body's cellular immune response.
[0076] In recent years, HTNV vaccines with new epitope designs have been explored at home and abroad, but from the application situation, such vaccines still have many shortcomings, the most important of which is that they cannot provide lasting immunity. Therefore, if the HTNV NP dominant MHC class II epitope peptides screened by the method of the present invention are used to activate the body's cellular immune response, they will have the following advantages:
[0077] (1) After viral infection, antigen presenting cells (APCs) activate CD4 through antigen presentation by MHC class II molecules + T cells. For MHC class II molecules, most MHC-II protein-bound peptides have 13-25 amino acid residues, with an average length of 15 residues. Therefore, we selected a 15-amino acid peptide as the predicted epitope. + T cells can activate CD8 through dendritic cells + T cell immune response, then CD8 + T cells recognize virus-infected cells (target cells), release perforins, granzymes and pass through the FasL-Fas pathway, causing target cell lysis and death, thereby effectively clearing the virus infection in the body.
[0078] (2) Vaccination with HTNV reduces the incidence of HFRS. Therefore, many studies have explored new Hantavirus vaccine candidates with novel epitope designs. These studies have mainly focused on CD8 + T cell and B cell mediated immune response. However, this type of vaccine still has many shortcomings, the most important of which is that it cannot provide long-lasting immunity. MHC-II can induce immune memory for long-term protection against HTNV, which requires CD4 + Memory T cells play a long-term role in prolonging the body's immunity.
[0079] (3) MHC class II molecules are crucial in the control of many immune responses. The affinity between MHC II and peptides is one of the key determinants of functional affinity. It has been shown that peptides with higher affinity binding to MHC are required for activating T cell responses. Currently, most epitope-related computer studies rely on a single tool, which may lead to biased analysis results. Therefore, we adopted an "integration" strategy in which four algorithms complement each other to obtain accurate analysis of the affinity between peptides and MHC II. Immunogenicity also plays an important role in the induction of strong immune responses by peptides, and peptides with high affinity do not always induce cellular immune responses. At the same time, we performed immunogenicity analysis on all predicted high-affinity 15 peptides to eliminate high-affinity non-immunogenic epitopes.
[0080] (4) Studies have shown that conserved epitopes can induce immune responses to interspecies viruses and increase the scope of protective immunity. We conducted a conservation analysis of 15 peptide dominant epitopes. Compared with other epitopes, conservative dominant epitopes are more suitable for vaccine development and immune research. 34 dominant epitopes with high affinity, strong immunogenicity, and conservation between and within species were simulated and docked with MHC class II molecules, indicating that the affinity prediction results and molecular docking calculations can be mutually verified, further demonstrating the feasibility of applying the 34 peptides to herd immunity and the potential of HTNV NP-derived pan-MHC II epitopes in vaccine development. ELISpot experiments verified that 9 of the dominant epitopes were able to induce strong immune responses in mouse spleen cells.
[0081] (5) Studies have shown that the antigenic site of HTNV NP is mainly located at the N-terminus, and the region of 1-37 amino acids is an important antigenic domain. Among the 9 15-peptide dominant epitopes predicted by us, 5 epitopes are in this antigenic domain. This shows that the method of the present invention can accurately predict the dominant epitopes on HTNV NP that can induce cellular immunity, find more antigenic epitopes with potential vaccine targets in a short time, and greatly save experimental costs.
[0082] The present invention is based on comparative immunology and structural immunology, utilizes the principle of molecular bioinformatics, and uses a variety of prediction tools to analyze the affinity, immunogenicity and conservation of 15 peptide dominant epitopes of HTNV NP. Simulation of docking of dominant epitope peptides with MHC class II molecules and mouse experimental verification are also performed, which provides a new idea for subsequent immunological research related to Hantavirus (HTNV76-118) and is helpful for the design of epitope-based anti-HTNV epitope vaccines in the future. At the same time, the analysis method of the present invention can also be used for basic research on other pathogens, prevention and control of infectious diseases, and treatment and intervention of tumors.
[0083] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0084] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. An MHC-II class antigenic nonapeptide, characterized in that The amino acid sequence of the nonapeptide is one of the following: SEQ ID NO.10: LVIARQKVR; SEQ ID NO.11: YVSLPNAQS; SEQ ID NO.12: ILQDMRNTI.
2. A gene encoding the MHC-II class antigenic nonapeptide according to claim 1.
3. A dominant epitope peptide of Hantavirus nucleocapsid protein comprising the nonapeptide of claim 1, characterized in that: The amino acid sequence of the dominant epitope peptide is one of the following: SEQ ID NO.1:NAHEGQLVIARQKVR; SEQ ID NO.2:AHEGQLVIA RQKVRD; SEQ ID NO.3: HEGQLVIARQKVRDA; SEQ ID NO.4: EGQLVIARQKVRDAE; SEQ ID NO.5: GQLVIARQKVRDAEK; SEQ ID NO.6: KPKHLYVSLPNAQSS; SEQ ID NO.7: LYVSLPNAQSSMKAE; SEQ ID NO.8: FSILQDMRNTIMASK; SEQ ID NO.9: SILQDMRNTIMASKT; Among them, the common amino acid fragments of the dominant epitope peptides shown in SEQ ID NO.1 to 5 are shown in SEQ ID NO.10, SEQ ID NO.6 to 7 contain the nonapeptide shown in SEQ ID NO.11, and the common amino acid fragments of the dominant epitope peptides shown in SEQ ID NO.8 to 9 are shown in SEQ ID NO.
12.
4. A gene encoding the dominant epitope peptide according to claim 3.
5. Use of the MHC-II class antigenic nonapeptide according to claim 1 or the dominant epitope peptide according to claim 3 in the preparation of anti-hantavirus products.
6. Use of the gene described in claim 2 or claim 4 in the preparation of anti-Hantavirus products.
7. The use according to claim 5 or claim 6, characterized in that: The product is an epitope vaccine.
8. A Hantavirus epitope vaccine, characterized in that: The immunogen is derived from the MHC-II class antigenic nonapeptide described in claim 1 or the dominant epitope peptide described in claim 3.
9. The Hantavirus epitope vaccine according to claim 8, characterized in that: The vaccine also includes a pharmaceutically acceptable carrier.
10. The Hantavirus epitope vaccine according to claim 9, characterized in that: The vaccine may or may not contain an adjuvant.
Citation Information
Cited By
Hantavirus nucleocapsid protein pan-MHC-I epitope peptide, vaccine and application
CN121293298A
